Part-Time

Oncology Physician Clinical Reviewer

Evolent

Evolent

1,001-5,000 employees

Delivers value-based care through analytics

Compensation Overview

$130 - $145/hr

+ Sign-on bonus

Company Does Not Provide H1B Sponsorship

Remote in USA

Remote

Final interviews may require on-site attendance.

MD

Category
Medical, Clinical & Veterinary (1)

Get referred to Evolent

See people who can refer or advise you

Requirements
  • MD, DO, or MBBS with board certification in Medical Oncology or Pediatric Oncology.
  • At least five years of post-residency experience.
  • A current, unrestricted medical license.
  • Demonstrated leadership in practice transformation, value-based care, or clinical quality improvement.
  • The ability to communicate, collaborate, and organize effectively, with a proven ability to influence physician behavior.
  • Not being under sanction or exclusion from Medicare or Medicaid programs.
  • Completion of government-issued photo ID submission and identity verification steps.
  • Completion of a comprehensive background check and in-person I-9 verification; candidates may also be subject to drug screening before employment.
  • High-speed home internet exceeding 10 Mbps; call center employees must be able to connect directly to the home internet router.
Responsibilities
  • Serve as the physician reviewer for oncology cases that do not initially meet medical necessity criteria, applying evidence-based guidelines to ensure high-quality and cost-effective care.
  • Conduct peer-to-peer discussions with requesting oncologists to explain determinations and promote practice patterns aligned with value and quality outcomes.
  • Support clinical reviewers as a subject matter expert and resource.
  • Participate in engagement sessions with oncology practices to share best clinical practices and support adoption of evidence-based pathways.
  • Build trusted peer relationships with oncologists to encourage sustainable behavior change that improves patient outcomes.
  • Support practice-level transformation initiatives that reduce unwarranted variation and enhance quality.
  • Collaborate with clinical leadership on the design, build, and execution of new value initiatives in oncology.
  • Provide input on innovation opportunities, clinical algorithms, and models of care supporting transformation in specialty care.
  • Partner with operational and analytic teams to assess intervention impact and identify opportunities for continuous improvement.
  • Participate in audit processes to validate the accuracy of advance payment model payouts against clinical documentation, performance metrics, and contractual expectations.
  • Ensure reviews and engagements align with URAC, NCQA, and internal quality standards.
  • Document peer interactions and clinical decisions accurately and promptly.
  • Participate in training and inter-rater reliability processes.
Desired Qualifications
  • Active clinical practice within the past two years is preferred.
  • Multiple state medical licenses are preferred.
  • Willingness to obtain multiple state medical licenses is preferred.

Evolent Health helps healthcare organizations transition to value-based care by pairing technology, analytics, and clinical expertise to improve patient outcomes while lowering costs. It partners with health systems, physician groups, and health plans to deliver data-driven care coordination, population health management, and risk-adjustment services. The company’s offerings include software platforms, analytics, and clinical support that enable more efficient care delivery, shared savings programs, and performance-based incentives. Compared with competitors, Evolent emphasizes end-to-end collaboration with clients and a diversified client base, combining technology with hands-on clinical and operational expertise to drive measurable outcomes. Its goal is to help clients succeed in value-based models by delivering better patient care at lower total costs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Arlington, Virginia

Founded

2011

Get referred to Evolent

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $652.5 million, and guidance rose to $2.65 billion.
  • Oncology agreement covers 1.5 million lives and targets $300 million annualized revenue.
  • AI automation and Auth Intelligence lifted efficiency, supporting 2027 EBITDA above $150 million.

What critics are saying

  • Q2 2026 net debt hit $808.3 million, forcing 2029 refinancing before growth stalls.
  • Medical expense pressure and 6.4x leverage threaten margins if claims deteriorate in 2026.
  • Any Highmark or Aetna contract failure would crush credibility and trigger covenant stress.

What makes Evolent unique

  • Evolent combines oncology, authorization automation, and value-based care under one payer-facing platform.
  • Archie Mayani joined March 2026, strengthening AI product execution across clinical workflows.
  • Highmark and Aetna launches prove Evolent wins large-plan integrations competitors still struggle to replicate.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Hybrid Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 15th, 2026
Evolent Health beats Q2 revenue estimates by 9.4%, raises full-year guidance to $2.65B

Evolent Health reported strong second-quarter results, beating revenue expectations with $652.5 million versus the anticipated $596.7 million, representing 46.9% year-on-year growth. The company also surpassed adjusted earnings per share and EBITDA forecasts. CEO Seth Blackley attributed the performance to successful contract launches with Highmark and robust customer renewals. Clinical engagement metrics for new partnerships with Aetna and Highmark exceeded targets, demonstrating strong execution in value-based care solutions. The company raised its full-year revenue guidance to $2.65 billion at the midpoint, up 6% from the previous $2.5 billion forecast. EBITDA guidance remained at $127.5 million. During the earnings call, management addressed analyst questions about reserving processes, margin trends in new contracts, and pipeline development. Blackley noted the business pipeline has refilled with several large national plans under consideration, particularly in oncology services.

Yahoo Finance
Aug 10th, 2026
Evolent Health beats revenue estimates with $652.5M, raises full-year guidance to $2.65B on AI automation gains

Evolent Health reported Q2 2026 revenue of $652.5 million, up 46.9% year-on-year and beating analyst estimates by 9.4%. The healthcare solutions company's full-year revenue guidance of $2.65 billion came in 5.9% above consensus. CEO Seth Blackley highlighted the successful launch of the Highmark contract and strong clinical engagement metrics for new partnerships with Aetna and Highmark. The company's Auth Intelligence automation platform contributed to operational efficiency gains. Management pointed to expansion of its oncology Performance Suite and accelerated deployment of its AI-enabled authorisation platform as key growth drivers. Blackley stated Q2 represented "a tipping point in our AI journey" as efforts moved beyond pilot phases to meaningful scale. The company expects cost-saving initiatives and improved operating leverage to offset headwinds from Medicaid and exchange membership pressures.

Yahoo Finance
Aug 6th, 2026
Evolent Health revenue surges 31% to $653M, raises 2026 guidance to $2.7B

Evolent Health reported strong second-quarter 2026 results, with total revenue reaching $653 million, up 31% from the previous quarter. Adjusted EBITDA rose 27% quarter-over-quarter to $28 million. The healthcare technology company raised its full-year 2026 revenue guidance to between $2.6 billion and $2.7 billion. It tightened adjusted EBITDA guidance to a range of $120 million to $135 million. Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualised revenue. The company also secured a contract extension with a regional Blue Cross plan. The firm ended Q2 with $115.7 million in unrestricted cash and $808.3 million of net debt. For 2027, Evolent expects revenue growth exceeding 25%.

Yahoo Finance
Jun 12th, 2026
Evolent Health posts weakest Q1 revenue growth among healthcare tech providers despite $496M earnings

Evolent Health reported Q1 revenues of $496.2 million, up 2.6% year on year, but falling short of analysts' expectations by 6.9%. The healthcare technology company, which provides specialty care management services for patients with complex conditions, delivered mixed results with an earnings per share beat but a significant revenue miss. The healthcare technology for providers sector showed overall strength in Q1, with the four tracked stocks beating revenue consensus estimates by 1.1% on average. Share prices have risen 7.7% on average since earnings results. Despite having the weakest performance against analyst estimates and slowest revenue growth in the group, Evolent Health raised its full-year guidance the most. The stock has climbed 21.5% since reporting and currently trades at $4.65.